vimarsana.com

Latest Breaking News On - Epidarex capital - Page 2 : vimarsana.com

Macomics Unveils Its Lead First-In-Class Anti-Pan-LILRB Monoclonal Antibody Programme With Positive Pre-Clinical Data Presented At AACR 2024

Macomics Unveils Its Lead First-In-Class Anti-Pan-LILRB Monoclonal Antibody Programme With Positive Pre-Clinical Data Presented At AACR 2024
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Curve Therapeutics: Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers

Curve Therapeutics: Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers

Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Curve Therapeutics raises £40 5 million to turbocharge discovery platform and advance breakthrough pipeline

Curve Therapeutics raises £40 5 million to turbocharge discovery platform and advance breakthrough pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Enterprise Therapeutics closes £26 million ($33 1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.